Literature DB >> 26971434

Fontan-associated liver disease: Spectrum of US findings.

Jung Min Bae1, Tae Yeon Jeon2, Jung Sun Kim3, Seokhwi Kim3, Sook Min Hwang1, So-Young Yoo1, Ji Hye Kim1.   

Abstract

PURPOSE: To describe ultrasonography (US) findings of Fontan-associated liver disease (FALD) and to determine whether screening US examinations can identify FALD before biochemical hepatic dysfunction.
METHODS: This retrospective study included 55 patients who underwent Fontan procedure over a 20-year period. Hepatobiliary US findings (n=55), CT or MRI findings (n=19), biochemical hepatic function tests (n=49), and histopathological results (n=4) were analyzed. Images were reviewed focusing on the hepatic parenchymal changes, presence of focal lesions, and signs of portal hypertension.
RESULTS: Hepatic parenchymal changes (either heterogeneous echotexture or surface nodularity) evident on US were present in 67% (37/55) and showed positive correlation with the Fontan duration. Hyper-echoic lesions were noted in 35% (19/55) and showed a predilection for multiplicity, small size, right lobe location, and irregular margin on high-frequency transducer. These lesions were not demonstrated by CT or MRI or by low-frequency transducer. Histopathological results of targeted biopsy for hyper-echoic lesions revealed lesser degree of patchy sinusoidal and portal fibrosis than seen in cases with surface nodularity. Abnormal parenchymal enhancement was commonly seen with CT or MRI in 63% (12/19) and hypervascular nodules in 21% (4/19). Most patients (82%, 40/49) showed normal biochemical hepatic function tests, despite the presence of hepatic parenchymal changes on imaging.
CONCLUSION: The common US findings of FALD included heterogeneous parenchymal echotexture, surface nodularity, and hyper-echoic lesions. We suggest that hyper-echoic lesions without surface nodularity detected by high-frequency transducer may represent the early stage of fibrosis. US examination may be useful for identifying the progression of FALD before biochemical hepatic dysfunction.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Fontan-associated liver disease; Hepatic fibrosis; US

Mesh:

Substances:

Year:  2016        PMID: 26971434     DOI: 10.1016/j.ejrad.2016.02.002

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  12 in total

1.  Forns Index is a predictor of cardiopulmonary bypass time and outcomes in Fontan conversion.

Authors:  Gaku Izumi; Atsuhito Takeda; Hirokuni Yamazawa; Osamu Sasaki; Nobuyasu Kato; Hidetsugu Asai; Tsuyoshi Tachibana; Yoshiro Matsui
Journal:  Heart Vessels       Date:  2019-09-27       Impact factor: 2.037

Review 2.  Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy.

Authors:  Alexander Lemmer; Lisa B VanWagner; Daniel Ganger
Journal:  Hepatology       Date:  2018-09-22       Impact factor: 17.425

3.  Vortex Flow in the Right Atrium Surrogates Supraventricular Arrhythmia and Thrombus After Atriopulmonary Connection-Type Fontan Operation: Vortex Flow Analysis Using Conventional Cine Magnetic Resonance Imaging.

Authors:  Yumi Shiina; Kei Inai; Tatsunori Takahashi; Yamato Shimomiya; Umiko Ishizaki; Kenji Fukushima; Michinobu Nagao
Journal:  Pediatr Cardiol       Date:  2017-11-02       Impact factor: 1.655

Review 4.  Screening modalities for the diagnosis of Fontan-associated liver disease: evidence from the past for future development.

Authors:  Saviga Sethasathien; Krit Leemasawat; Suchaya Silvilairat; Rekwan Sittiwangkul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

5.  Non-invasive assessment of liver alterations in Senning and Mustard patients.

Authors:  Nicole Nagdyman; Siegrun Mebus; Johanna Kügel; Reinhart Zachoval; Dirk-André Clevert; Siegmund Lorenz Braun; Guido Haverkämper; Bernd Opgen-Rhein; Felix Berger; Sophia Horster; Jörg Schoetzau; Claudia Pujol Salvador; Ulrike Bauer; John Hess; Peter Ewert; Harald Kaemmerer
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

6.  30-year experience of Fontan surgery: single-centre's data.

Authors:  Laurynas Bezuska; Virgilijus Lebetkevicius; Rita Sudikiene; Daina Liekiene; Virgilijus Tarutis
Journal:  J Cardiothorac Surg       Date:  2017-08-09       Impact factor: 1.637

7.  Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

Authors:  Amyna Fidai; Frederic Dallaire; Nanette Alvarez; Yvonne Balon; Robin Clegg; Michael Connelly; Frank Dicke; Deborah Fruitman; Joyce Harder; Kimberley Myers; David J Patton; Tim Prieur; Erika Vorhies; Robert P Myers; Steven R Martin; Steven C Greenway
Journal:  Front Cardiovasc Med       Date:  2017-03-27

Review 8.  Abdominal imaging findings in adult patients with Fontan circulation.

Authors:  Tae-Hyung Kim; Hyun Kyung Yang; Hyun-Jung Jang; Shi-Joon Yoo; Korosh Khalili; Tae Kyoung Kim
Journal:  Insights Imaging       Date:  2018-04-05

9.  Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

Authors:  Anastasia Schleiger; Madeleine Salzmann; Peter Kramer; Friederike Danne; Stephan Schubert; Christian Bassir; Tobias Müller; Hans-Peter Müller; Felix Berger; Stanislav Ovroutski
Journal:  Pediatr Cardiol       Date:  2020-02-01       Impact factor: 1.655

10.  Fontan-associated liver disease and hepatocellular carcinoma in adults.

Authors:  Tomomi Kogiso; Katsutoshi Tokushige
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.